<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02794779</url>
  </required_header>
  <id_info>
    <org_study_id>anestesiatccthiago1416</org_study_id>
    <nct_id>NCT02794779</nct_id>
  </id_info>
  <brief_title>Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial</brief_title>
  <acronym>MODCL</acronym>
  <official_title>Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brasilia University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brasilia University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: postpartum hemorrage is a leading cause of death after cesarean sections in
      Brazil. Oxytocin is the main drug for both prophylaxis and threatment of postpartum hemorrage
      because uterine atony is the most prevalent cause. Both excessive and too low oxytocin doses
      threaten the life of women.

      Objective: to determine the minimum effective dose of oxytocin for cesareans during labor.

      Method: adaptative clinical trial using a modified up and down method of two sequential
      groups: rule of three and continuous infusion. Allocation in rule of three or continuous
      infusion will be random and masked for patients and anesthesiologists. The minimum effective
      dose will be the effective dose for 90% of success (ED90 for preventing uterine atony).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxytocin dose</measure>
    <time_frame>10 minutes</time_frame>
    <description>Minumum oxytocin dose for preventing uterine atony in 90% of cesareans.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cesarean Section During Labor</condition>
  <arm_group>
    <arm_group_label>Rule of three</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.</description>
    <arm_group_label>Rule of three</arm_group_label>
    <arm_group_label>Continuous infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cesarean delivery during labor.

          -  Spinal anesthesia

        Exclusion Criteria:

          -  Change of anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel MN Guimaraes, MD, MSc</last_name>
    <phone>+5561996455997</phone>
    <email>gabrielmng@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helga BG Silva, MD, PhD</last_name>
    <phone>5561991755997</phone>
    <email>helgabgs@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitário de Brasília</name>
      <address>
        <city>Brasilia</city>
        <state>Distrito Federal</state>
        <zip>70000000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel MN Guimaraes, MD MsC</last_name>
      <phone>6196455997</phone>
      <email>gabrielmng@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2016</study_first_submitted>
  <study_first_submitted_qc>June 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brasilia University Hospital</investigator_affiliation>
    <investigator_full_name>Gabriel Magalhaes Nunes Guimaraes</investigator_full_name>
    <investigator_title>MD, MSc</investigator_title>
  </responsible_party>
  <keyword>cesarean section</keyword>
  <keyword>labor</keyword>
  <keyword>oxytocin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

